Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients

References

• Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6:859–866.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;18–25:87–89.
   Google Scholar
• Looney RJ. Treating human autoimmune disease by depleting B cells. Ann Rheum Dis. 2002;61:863–866.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Taylor RP, Cascavilla N, et al. Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia? Endocr Metab Immune Disord Drug Targets 2008;8:62–68.
   PubMedGoogle Scholar
• Yadav AR, Deo N. Rituximab therapy and autoimmune disease. CIR. 2012;8:94–100.
   Google Scholar
• Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med. 2013;11:88
   PubMed Web of Science ®Google Scholar
• D’Arena G, Di Minno MND, Grandone E, et al. Anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A. Blood Transfus. 2016;14:255–261.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). V 4.02. [Internet]. 2009. [cited 2012 Nov 2]. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/.
   Google Scholar
• Coiffier B, Lepage E, Briere R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematol Am Soc Hematol Edu Program. 2007;2007:233–242. doi: 10.1182/asheducation-2007.1.233
   Google Scholar
• Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol. 2008;141:149–169.
   PubMed Web of Science ®Google Scholar
• Dorner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol. 2009;5:433–441.
   PubMed Web of Science ®Google Scholar
• Kimby E. Tolerability and safety of rituximab (Mab Thera®). Canc Treat Rev. 2005;31:456–473.
   PubMed Web of Science ®Google Scholar
• Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C298). Blood. 1999;94:2217–2224.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. JCO. 1999;17:791–795.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol. 1999;26:79–87.
   PubMed Web of Science ®Google Scholar
• Brown BA, Torabi M. Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre. Drug Saf. 2011;34:117–123.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–688.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, doucle-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–2806.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222–233.
   PubMed Web of Science ®Google Scholar
• Tony HP, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther. 2011;13:R75.
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Steponski EJ, Fortner BV, et al. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices; assessment of clinical consequences. Support Care Cancer. 2008;16:393–398.
   PubMed Web of Science ®Google Scholar
• D’Arena G, De Lorenzo S, Vigliotti ML, et al. Drug-related side effects after rituximab infusion in patients with chronic lymphocytic leukemia. Eur J Oncol. 2015;20:64–67.
   Google Scholar
• Norin S, Bjorkstrand B, Rommel F, et al. Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study. Leuk Res. 2015;39:33–37.
   PubMed Web of Science ®Google Scholar
• Puxeddu I, Caltran E, Rocchi V, et al. Hypersensitivity reactions during treatment with biological agents. Clin Exp Pathol. 2016;34:129–132.
   Google Scholar
• Pfreundschub M, Muller C, Zeynalova S, et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 2014;123:640–646.
   PubMed Web of Science ®Google Scholar
• Habermann TM. Is rituximab one for all ages and each sex?. Blood. 2014;123:602–603.
   PubMed Web of Science ®Google Scholar
• Salar A, Avivi I, Bittner B, et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol. 2014;32:1782–1791.
   PubMed Web of Science ®Google Scholar
• Davies A, Merli F, Mihaljevic B, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2014;15:343–352.
   PubMed Web of Science ®Google Scholar